JPWO2019141732A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019141732A5 JPWO2019141732A5 JP2020559030A JP2020559030A JPWO2019141732A5 JP WO2019141732 A5 JPWO2019141732 A5 JP WO2019141732A5 JP 2020559030 A JP2020559030 A JP 2020559030A JP 2020559030 A JP2020559030 A JP 2020559030A JP WO2019141732 A5 JPWO2019141732 A5 JP WO2019141732A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody molecule
- acid sequence
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 description 80
- 102000004965 antibodies Human genes 0.000 description 80
- 125000003275 alpha amino acid group Chemical group 0.000 description 53
- 206010000830 Acute leukaemia Diseases 0.000 description 27
- 102100016384 HAVCR2 Human genes 0.000 description 20
- 101710004393 HAVCR2 Proteins 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 17
- 102100013078 CD47 Human genes 0.000 description 15
- 101700033237 CD47 Proteins 0.000 description 15
- 102100004476 SIRPA Human genes 0.000 description 15
- 101710024246 SIRPA Proteins 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 102100005830 CD70 Human genes 0.000 description 14
- 101700017377 CD70 Proteins 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 230000011664 signaling Effects 0.000 description 11
- 102100018956 IL1RAP Human genes 0.000 description 10
- 101710008035 IL1RAP Proteins 0.000 description 10
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 8
- 102100010013 LILRB2 Human genes 0.000 description 8
- 101710002780 LILRB2 Proteins 0.000 description 8
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 8
- 101710015837 LGALS9 Proteins 0.000 description 7
- 102100004651 LGALS9 Human genes 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 102000037240 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 102100002977 CDR1 Human genes 0.000 description 5
- 101700073818 CDR1 Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002397 Granulocyte Precursor Cells Anatomy 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 229910021320 cobalt-lanthanum-strontium oxide Inorganic materials 0.000 description 3
- 210000001167 myeloblast Anatomy 0.000 description 3
- 102100000097 ADGRE2 Human genes 0.000 description 2
- 101710005034 ADGRE2 Proteins 0.000 description 2
- 102100010882 ADGRG1 Human genes 0.000 description 2
- 101710005049 ADGRG1 Proteins 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 101700076092 CCR1 Proteins 0.000 description 2
- 101700083927 CCR1 Proteins 0.000 description 2
- 102100005860 CCR1 Human genes 0.000 description 2
- 102100016493 CD33 Human genes 0.000 description 2
- 101700017647 CD33 Proteins 0.000 description 2
- 101700078950 CD44 Proteins 0.000 description 2
- 102100003735 CD44 Human genes 0.000 description 2
- 101710026045 CD96 Proteins 0.000 description 2
- 102100014435 CD96 Human genes 0.000 description 2
- 102100013153 CLEC12A Human genes 0.000 description 2
- 101710010518 CLEC12A Proteins 0.000 description 2
- 102100002212 CXCR4 Human genes 0.000 description 2
- 101710003734 CXCR4 Proteins 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 101710044640 FCGR2A Proteins 0.000 description 2
- 101710044641 FCGR2B Proteins 0.000 description 2
- 102100015544 FCGR2C Human genes 0.000 description 2
- 101710044642 FCGR2C Proteins 0.000 description 2
- 101700082799 IL2RA Proteins 0.000 description 2
- 102100002950 ISG20 Human genes 0.000 description 2
- 101700015336 ISG20 Proteins 0.000 description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- 229950010895 Midostaurin Drugs 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 229940121655 PD-1 inhibitors Drugs 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 229940121656 PD-L1 inhibitors Drugs 0.000 description 2
- 101700071234 RBG8 Proteins 0.000 description 2
- 102100003520 SELE Human genes 0.000 description 2
- 108009000607 Wnt Signaling Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 102000015735 beta Catenin Human genes 0.000 description 2
- 108060000903 beta Catenin Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 229950002916 Avelumab Drugs 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 101700056583 CD27 Proteins 0.000 description 1
- 102100019459 CD27 Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 102000004851 Immunoglobulin G Human genes 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 108010019706 Nivolumab Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102100003105 TNFRSF1B Human genes 0.000 description 1
- 101710038524 TNFRSF1B Proteins 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 108010072668 atezolizumab Proteins 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 108010010826 avelumab Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 230000002071 myeloproliferative Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 108010026276 pembrolizumab Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023202413A JP2024037765A (ja) | 2018-01-16 | 2023-11-30 | Ｃｄ７０組合せ療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1800649.4A GB201800649D0 (en) | 2018-01-16 | 2018-01-16 | CD70 Combination Therapy |
| GB1800649.4 | 2018-01-16 | ||
| PCT/EP2019/051058 WO2019141732A1 (en) | 2018-01-16 | 2019-01-16 | Cd70 combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202413A Division JP2024037765A (ja) | 2018-01-16 | 2023-11-30 | Ｃｄ７０組合せ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510736A JP2021510736A (ja) | 2021-04-30 |
| JPWO2019141732A5 true JPWO2019141732A5 (ko) | 2022-02-09 |
| JP7511479B2 JP7511479B2 (ja) | 2024-07-05 |
Family
ID=61256176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559030A Active JP7511479B2 (ja) | 2018-01-16 | 2019-01-16 | Ｃｄ７０組合せ療法 |
| JP2023202413A Pending JP2024037765A (ja) | 2018-01-16 | 2023-11-30 | Ｃｄ７０組合せ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202413A Pending JP2024037765A (ja) | 2018-01-16 | 2023-11-30 | Ｃｄ７０組合せ療法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11530271B2 (ko) |
| EP (2) | EP3740504B9 (ko) |
| JP (2) | JP7511479B2 (ko) |
| KR (1) | KR20200110658A (ko) |
| CN (1) | CN111836830B (ko) |
| AU (1) | AU2019209503A1 (ko) |
| BR (1) | BR112020014321A2 (ko) |
| CA (1) | CA3086448A1 (ko) |
| DK (1) | DK3740504T5 (ko) |
| EA (1) | EA202091714A1 (ko) |
| ES (1) | ES2956258T3 (ko) |
| FI (1) | FI3740504T3 (ko) |
| GB (1) | GB201800649D0 (ko) |
| HU (1) | HUE063783T2 (ko) |
| IL (1) | IL276103A (ko) |
| LT (1) | LT3740504T (ko) |
| MX (1) | MX2020007606A (ko) |
| PL (1) | PL3740504T3 (ko) |
| PT (1) | PT3740504T (ko) |
| SG (1) | SG11202006007YA (ko) |
| WO (1) | WO2019141732A1 (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2670874T3 (es) | 2011-03-16 | 2018-06-01 | Argenx Bvba | Anticuerpos contra CD70 |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| CN110997725B (zh) | 2017-06-12 | 2024-08-09 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| JP2022548627A (ja) * | 2019-09-16 | 2022-11-21 | ノバルティス アーゲー | 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用 |
| US20230058489A1 (en) * | 2020-01-17 | 2023-02-23 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| JP2023524811A (ja) * | 2020-05-05 | 2023-06-13 | ティーシーアール２ セラピューティクス インク． | Ｃｄ７０特異的融合タンパク質を使用したｔｃｒリプログラミングのための組成物及び方法 |
| CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
| JP2024527551A (ja) * | 2021-06-29 | 2024-07-25 | シージェン インコーポレイテッド | 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法 |
| WO2024126833A1 (en) * | 2022-12-16 | 2024-06-20 | Ichnos Sciences SA | Cd47-il1rap bispecific antibodies |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| US20070072178A1 (en) | 2001-11-05 | 2007-03-29 | Torsten Haferlach | Novel genetic markers for leukemias |
| US20050118656A1 (en) | 2001-11-27 | 2005-06-02 | Terrett Jonathan A. | Methods for diagnosis and treatment of epithelial-derived cancers |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| WO2006044643A2 (en) | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
| WO2006113747A2 (en) | 2005-04-19 | 2006-10-26 | Prediction Sciences Llc | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| US20080280297A1 (en) | 2005-07-15 | 2008-11-13 | The Trustees Of Columbia University In The City Of | Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| KR100807069B1 (ko) | 2007-09-21 | 2008-02-25 | 고려대학교 산학협력단 | 암 치료용 의약 조성물 |
| EA201000673A1 (ru) | 2007-11-05 | 2011-04-29 | Новартис Аг | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2010014948A1 (en) | 2008-08-01 | 2010-02-04 | The University Of Utah Research Foundation | Methods of treatment using wnt inhibitors |
| US20110190157A1 (en) | 2008-08-15 | 2011-08-04 | The Regents Of The University Of California | Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia |
| RU2579897C2 (ru) | 2008-09-26 | 2016-04-10 | Онкомед Фармасьютикалс, Инк. | Агенты, связывающие рецептор "frizzled", и их применение |
| EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
| CN102595900B (zh) | 2009-08-10 | 2015-07-15 | 萨穆梅德有限公司 | Wnt信号传导途径的吲唑抑制剂及其治疗用途 |
| WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| CN102665759B (zh) | 2009-11-19 | 2015-09-30 | 默克雪兰诺有限公司 | 人源化抗il-22ra抗体 |
| EP2520589B1 (en) | 2009-12-29 | 2018-11-07 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| KR101989134B1 (ko) | 2011-01-19 | 2019-06-13 | 칸타르기아 아베 | 항―ｉｌ１ｒａｐ 항체 및 그의 인간 치료 용도 |
| ES2670874T3 (es) | 2011-03-16 | 2018-06-01 | Argenx Bvba | Anticuerpos contra CD70 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| EA201790757A1 (ru) | 2011-09-22 | 2017-07-31 | Эмджен Инк. | Связывающие антиген cd27l белки |
| EA030828B1 (ru) | 2012-03-15 | 2018-10-31 | Янссен Байотек, Инк. | Человеческие антитела к cd27, методы и применение |
| EP2827878A1 (en) | 2012-03-21 | 2015-01-28 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
| WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| DK2956173T3 (en) | 2013-02-14 | 2017-07-17 | Bristol Myers Squibb Co | TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| SG11201607143UA (en) * | 2014-03-11 | 2016-09-29 | Univ Leland Stanford Junior | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| US20180244792A1 (en) * | 2015-09-10 | 2018-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| CR20180234A (es) * | 2015-11-03 | 2018-09-11 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
-
2018
- 2018-01-16 GB GBGB1800649.4A patent/GB201800649D0/en not_active Ceased
-
2019
- 2019-01-16 JP JP2020559030A patent/JP7511479B2/ja active Active
- 2019-01-16 SG SG11202006007YA patent/SG11202006007YA/en unknown
- 2019-01-16 MX MX2020007606A patent/MX2020007606A/es unknown
- 2019-01-16 WO PCT/EP2019/051058 patent/WO2019141732A1/en unknown
- 2019-01-16 FI FIEP19702014.2T patent/FI3740504T3/fi active
- 2019-01-16 EA EA202091714A patent/EA202091714A1/ru unknown
- 2019-01-16 PL PL19702014.2T patent/PL3740504T3/pl unknown
- 2019-01-16 LT LTEPPCT/EP2019/051058T patent/LT3740504T/lt unknown
- 2019-01-16 EP EP19702014.2A patent/EP3740504B9/en active Active
- 2019-01-16 HU HUE19702014A patent/HUE063783T2/hu unknown
- 2019-01-16 CN CN201980018288.6A patent/CN111836830B/zh active Active
- 2019-01-16 ES ES19702014T patent/ES2956258T3/es active Active
- 2019-01-16 EP EP23177089.2A patent/EP4275702A3/en active Pending
- 2019-01-16 DK DK19702014.2T patent/DK3740504T5/da active
- 2019-01-16 CA CA3086448A patent/CA3086448A1/en active Pending
- 2019-01-16 US US16/249,480 patent/US11530271B2/en active Active
- 2019-01-16 BR BR112020014321-9A patent/BR112020014321A2/pt unknown
- 2019-01-16 PT PT197020142T patent/PT3740504T/pt unknown
- 2019-01-16 AU AU2019209503A patent/AU2019209503A1/en active Pending
- 2019-01-16 KR KR1020207021983A patent/KR20200110658A/ko not_active Application Discontinuation
-
2020
- 2020-07-16 IL IL276103A patent/IL276103A/en unknown
-
2022
- 2022-11-10 US US18/054,198 patent/US20240002523A1/en active Pending
-
2023
- 2023-11-30 JP JP2023202413A patent/JP2024037765A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Recent advances and challenges of bispecific antibodies in solid tumors | |
| KR102255616B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| JP2019536470A5 (ko) | ||
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| JP2018506964A5 (ko) | ||
| MX2014011190A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
| JPWO2019129221A5 (ko) | ||
| MX2014011274A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| Lim et al. | The promise of bispecific antibodies: Clinical applications and challenges | |
| JPWO2019141732A5 (ko) | ||
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| EP1885396A2 (en) | Recombinant antibodies against cd55 and cd59 and uses thereof | |
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| US20240002539A1 (en) | Multispecific antibodies and uses thereof | |
| JPWO2019224711A5 (ko) | ||
| TW202208429A (zh) | 用於治療多發性骨髓瘤之方法 | |
| CN116829186A (zh) | 多特异性抗体及其用途 | |
| EP4069298A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| JPWO2019222082A5 (ko) | ||
| WO2023206350A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| JPWO2020127503A5 (ko) | ||
| JP2023530720A (ja) | Ｌｅｗｉｓ Ｙに対するヒト化抗体 | |
| JPWO2020123664A5 (ko) |